February 24, 2017
Ontario will become the first Canadian province to reimburse for Zepatier in the treatment of chronic hepatitis C, effective Feb. 28, 2017, followed by British Columbia on Mar. 21, 2017, according to a press release from Merck.
Zepatier (elbasvir/grazoprevir, Merck Canada) is a once-daily pill to be taken for 12 weeks. It is indicated in the treatment of chronic HCV genotypes 1, 3 or 4 infections in adult patients and has no ribavirin regimen for most patients.